Literature DB >> 28024097

Immunoglobulin A: magic bullet or Trojan horse?

Marieke H Heineke1, Marjolein van Egmond1,2.   

Abstract

BACKGROUND: Neutrophils participate in the first line of defense by executing several killing mechanisms, including phagocytosis, degranulation and the release of neutrophil extracellular traps. Additionally, they can orchestrate the adaptive immune system by secreting cytokines and chemokines. Opsonization with antibodies aids in the recognition of pathogens, via binding to Fc receptors on the neutrophil surface. Immunoglobulin A (IgA) is the most abundant antibody at mucosal sites and has multiple functions in homeostasis and immunity. Neutrophils and IgA can interact via the IgA Fc receptor Fc?RI (CD89), leading to pro- or anti-inflammatory responses. AIMS: The aim of this review is to give a concise overview of the interplay between IgA, Fc?RI and neutrophils and to explore potential therapies for autoimmune diseases and cancer.
RESULTS: Crosslinking of FcαRI by IgA-immune complexes yields potent neutrophil activation and pro-inflammatory effector functions, including the recruitment of neutrophils. This can lead to neutrophil accumulation and tissue destruction during IgA-autoantibody mediated diseases. Conversely, for cancer treatment, the myriad of powerful neutrophil effector functions after targeting FcαRI may contribute to effective immunotherapy.
CONCLUSION: By interfering with or actively promoting the interaction between IgA and FcαRI, therapies for multiple maladies could be developed.
© 2016 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Autoimmune disease; CD89; FcαRI; cancer; immunoglobulin A; neutrophil

Mesh:

Substances:

Year:  2017        PMID: 28024097     DOI: 10.1111/eci.12716

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  23 in total

Review 1.  Nanodrugs Targeting T Cells in Tumor Therapy.

Authors:  Maximilian Haist; Volker Mailänder; Matthias Bros
Journal:  Front Immunol       Date:  2022-05-25       Impact factor: 8.786

2.  Rabbit IgA Hinges That Resist IgA1 Protease Action Provide Options for Improved IgA-Based Therapeutic Agents.

Authors:  Patrícia de Sousa-Pereira; Dennis K Lanning; Pedro J Esteves; Christian Spoerry; Jenny M Woof; Ana Pinheiro
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

Review 3.  Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Authors:  Michael J E Marshall; Richard J Stopforth; Mark S Cragg
Journal:  Front Immunol       Date:  2017-10-04       Impact factor: 7.561

4.  A generalized quantitative antibody homeostasis model: maintenance of global antibody equilibrium by effector functions.

Authors:  József Prechl
Journal:  Clin Transl Immunology       Date:  2017-11-17

5.  Extracellular Sphingomyelinase Rv0888 of Mycobacterium tuberculosis Contributes to Pathological Lung Injury of Mycobacterium smegmatis in Mice via Inducing Formation of Neutrophil Extracellular Traps.

Authors:  Guanghui Dang; Yingying Cui; Lei Wang; Tiantian Li; Ziyin Cui; Ningning Song; Liping Chen; Hai Pang; Siguo Liu
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 6.  dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.

Authors:  Óscar Palomares; Silvia Sánchez-Ramón; Ignacio Dávila; Luis Prieto; Luis Pérez de Llano; Marta Lleonart; Christian Domingo; Antonio Nieto
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

7.  Neutrophils kill the parasite Trichomonas vaginalis using trogocytosis.

Authors:  Frances Mercer; Shek Hang Ng; Taylor M Brown; Grace Boatman; Patricia J Johnson
Journal:  PLoS Biol       Date:  2018-02-06       Impact factor: 8.029

8.  Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI.

Authors:  Fabian Bohländer; Dennis Riehl; Sabrina Weißmüller; Marcus Gutscher; Jörg Schüttrumpf; Stefanie Faust
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 9.  Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.

Authors:  Juan C Almagro; Tracy R Daniels-Wells; Sonia Mayra Perez-Tapia; Manuel L Penichet
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

Review 10.  Immunoglobulin A and liver diseases.

Authors:  Tatsuo Inamine; Bernd Schnabl
Journal:  J Gastroenterol       Date:  2017-10-26       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.